Lil­ly, No­vo Nordisk, Sanofi CEOs to face off with Bernie Sander­s' health com­mit­tee in May

Sen. Bernie Sanders (I-VT), chair of the Sen­ate health com­mit­tee, an­nounced this af­ter­noon that his com­mit­tee will take a deep­er look in­to the high cost of in­sulin, and will haul in the CEOs from the ma­jor in­sulin man­u­fac­tur­ers Eli Lil­ly, No­vo Nordisk and Sanofi, as well as the top ex­ec­u­tives from the ma­jor phar­ma­cy ben­e­fit man­agers of CVS Health, Ex­press Scripts, and Op­tum­RX.

All six ex­ec­u­tives will face ques­tions from Sanders’ com­mit­tee on Wednes­day, May 10, as Con­gress eyes more leg­is­la­tion to ex­tend a $35 per month cap on in­sulin costs that’s now avail­able for se­niors in Medicare.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER